Idogen’s cash is estimated to last until June and the company is currently working with various financing alternatives.

Idogen’s work with capitalization is not yet finalized. The cash is estimated to last until the end of June. Idogen is working in parallel with various financing alternatives.

”We are working with several alternatives but have not yet reached a conclusion. In order to make the cash last longer, we have reduced costs as well as sold instruments and consumables. In our judgement, the cash will last until end of June. We are, as it should be in these type of situations, in dialogue with both our Certified Advisor as we all as with Nasdaq” says Christina Herder, acting CEO.

For further information, please contact:

Christina Herder, acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

The information was submitted for publication through the agency of the contact persons set out above on April 3, 2023, at 15:16 CET.

Certified Adviser:

Vator Securities AB

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced program, IDO 8 – now in clinical phase – is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company’s technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID). More information about Idogen is available via www.idogen.com.